ClinicalTrials.gg
Status unknownNCT05082168PROFICIENTUpdated Oct 18, 2021

Capnodynamic Monitoring of Cardiorespiratory Function in Critically Ill Patients

An observational study in Acute Respiratory Infection, Sepsis and Postoperative Respiratory Distress, sponsored by South West Sydney Local Health District. Status unknown at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-18.

Sponsored by South West Sydney Local Health District · Observational

How we know

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Sepsis with a site in Australia — 7 open to participants now, 8 under way, 1 of them phase 3. Sepsis · Australia.

Planned enrollment
10th of 11
100 · median 414
Started
2021
with 1 other
Observational
11 of 47
3 open now
Registered
39th of 47
by date

Among the 47 studies in Sepsis with a site in Australia, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2021, is one of 11 observational ones, and was the 39th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

7 of the 47 studies in Sepsis with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Sepsis with a site in Australia, or all of them as a file.
02

Study summary

Capnodynamic monitoring has the potential to offer continuous and non-invasive measurements of heart and lung function in patients requiring ventilation in an intensive care setting. Since mechanical ventilation with full patient synchronization is commonly used in ICU, capnodynamic monitoring can be immediately embedded in clinical care and compared to current methods of monitoring cardiac output, lung volumes and oxygen delivery. This observational study will explore capnodynamic monitoring in mechanically ventilated patients with a range of cardiorespiratory compromise.

Read the detailed description

This study aims to:

  1. compare the estimation of cardiac output (CO) using the capnodynamic method (COEPBF) with contemporary reference methods;
  2. compare the estimation of mixed venous oxygen saturation (SmvO2) with invasively obtained blood gas analyses;
  3. generate observational data on end-expiratory lung volume (EELV) when ventilator settings, and in particular PEEP, are changed;
  4. combine 1-3 to provide a physiological construct of cardiorespiratory function
03

Conditions studied

  • Acute Respiratory Infection
  • Sepsis
  • Postoperative Respiratory Distress

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to ICU for mechanical ventilation with a diagnosis of viral/bacterial pneumonia, sepsis or following cardiac surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Respiratory tract infection:

  1. confirmed or highly suspected viral or bacterial pneumonia
  2. meeting ARF or ARDS criteria as outlines in the most recent Berlin ARDS consensus statement
  3. age 18 years or above
  4. arterial and central venous catheters have been inserted or will be inserted as part of routine clinical management
  5. mechanical ventilation via an endotracheal tube is expected to continue for the day beyond day of admission
  6. adequate transthoracic echocardiographic winds are available to measure the velocity time integral in the left ventricular outflow tract
  7. analgosedation is administered as part of routine management of residual neuromuscular blockaded initiated outside ICU OR the administration of analgosedation and/or neuromuscular blockers at doses that achieve full patient-ventilator synchrony are considered part of routine clinical management

Sepsis:

  1. admitted to ICU with a provisional or established diagnosis of septic shock as defined by the Sepsis-3 criteria
  2. age 18 years or above
  3. arterial and central venous catheters have been inserted or will be inserted as part of routine clinical management
  4. mechanical ventilation via an endotracheal tube is expected to continue for at least another two hours
  5. adequate transthoracic echocardiographic winds are available to measure the velocity time integral in the left ventricular outflow tract
  6. analgosedation is administered as part of routine management of residual neuromuscular blockaded initiated outside ICU OR the administration of analgosedation and/or neuromuscular blockers at doses that achieve full patient-ventilator synchrony are considered part of routine clinical management
  7. the administration of a fluid bolus (250 ml or 500 ml) is indicated as judged by the medical officer supervising routine management

Cardiac surgery:

  1. admitted to ICU following cardiac surgery using cardiopulmonary bypass
  2. age 18 years and above
  3. arterial, central venous and pulmonary arterial catheters have been inserted or will be inserted as part of routine clinical management
  4. mechanical ventilation via an endotracheal tube is expected to continue for at least another two hours
  5. analgosedation is administered as part of routine management of residual neuromuscular blockade initiated intraoperatively OR the administration of analgosedation and/or neuromuscular blockers at doses that achieve full patient-ventilator synchrony are considered part of routine clinical management
  6. the administration of a fluid bolus (250 ml or 500 ml) is indicated as judged by the medical officer supervising routine postoperative management

Exclusion criteria

Exclusion Criteria:

In all cohorts:

  1. age under 18 years
  2. known pregnancy
  3. arterial and central venous catheters are not indicated as part of routine care
  4. known severe valvulopathy
  5. ongoing or imminent need for mechanical circulatory support
  6. severe haemodynamic instability with imminent transfer for intervention(s) outside ICU
  7. patient is not for full active management in ICU
  8. patient is not expected to live beyond the day of admission
  9. patient is re-admitted to ICU within the same index hospital admission
  10. it is not possible to achieve full patient-ventilator synchrony
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Respiratory tract infection

    Patients diagnosed with viral or bacterial pneumonia and admitted to ICU for mechanical ventilatory support

    Device: Capnodynamic monitoring

  • Sepsis

    Patients diagnosed with sepsis and admitted to ICU for mechanical ventilatory support

    Device: Capnodynamic monitoring

  • Cardiac surgery

    Patients admitted to ICU for mechanical ventilatory support following cardiac surgery

    Device: Capnodynamic monitoring

Interventions

  • DeviceCapnodynamic monitoring

    In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation: ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2.

    Also known as: thermodilution cardiac output measurement, echocardiography, blood gas analyses

06

What researchers measure

Primary outcomes

  1. Correlation between capnodynamic effective pulmonary blood flow and cardiac output measured by pulmonary artery thermodilution or echocardiography

    Capnodynamic measurements of effective pulmonary blood flow are compared with contemporaneously obtained cardiac output measurements using clinical reference methods

    Time frame: Through study completion, an average of 1 year

  2. Correlation between capnodynamic estimates of mixed venous oxygen saturation and blood gas analysis of blood obtained from the pulmonary artery pulmonary.

    Capnodynamic estimates of mixed venous oxygen saturation are compared with contemporaneously obtained blood gases from the pulmonary artery catheter

    Time frame: Through study completion, an average of 1 year

  3. Prediction by capnodynamic monitoring of combined changes in end expiratory lung volume and effective pulmonary blood flow to assess changes in pulmonary gas exchange during various levels of PEEP

    At three different levels of PEEP, the interactions between end expiratory lung volume and effective pulmonary blood flow will be assessed and correlated to changes in arterial partial pressure of oxygen and carbon dioxide

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Intensive Care Unit, Liverpool Hospital, South Western Sydney Local Health District
    Liverpool, New South Wales 1871, Australia
    Recruiting
08

References and documents

Publications

  • Schulz L, Stewart A, O'Regan W, McCanny P, Austin D, Hallback M, Wallin M, Aneman A. Capnodynamic monitoring of lung volume and blood flow in response to increased positive end-expiratory pressure in moderate to severe COVID-19 pneumonia: an observational study. Crit Care. 2022 Jul 31;26(1):232. doi: 10.1186/s13054-022-04110-0. PubMed 35909174 ↗

Individual participant data

Plan to share: Undecided — Upon reasonable request, IPD may be shared if fully compliant with HREC requirements and European GRDP regulations

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2022, 22 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 22 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Oct 18, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Dec 31, 2022
CompletionEst.
Jul 1, 2023
Last update
Oct 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05082168
Lead sponsor
South West Sydney Local Health District
Responsible party
Anders Aneman (Conj Professor UNSW, Director ICU Research, Senior Staff Specialist, South West Sydney Local Health District) — Principal investigator
First posted
Oct 18, 2021
Start date
Feb 1, 2021
Primary completion
Dec 31, 2022 (estimated)
Completion
Jul 1, 2023 (estimated)
Last update
Oct 18, 2021

Study contacts

Anders Aneman, Prof
Contact
anders.aneman@health.nsw.gov.au
+61 (0)2 87383400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion